Last reviewed · How we verify
Tinzaparin continuous infusion
Tinzaparin is a low-molecular-weight heparin that inhibits blood coagulation by enhancing the activity of antithrombin III against factors Xa and IIa.
Tinzaparin is a low-molecular-weight heparin that inhibits blood coagulation by enhancing the activity of antithrombin III against factors Xa and IIa. Used for Venous thromboembolism (VTE) treatment and prevention, Deep vein thrombosis (DVT) treatment, Pulmonary embolism (PE) treatment.
At a glance
| Generic name | Tinzaparin continuous infusion |
|---|---|
| Sponsor | Tampere University Hospital |
| Drug class | Low-molecular-weight heparin (LMWH) |
| Target | Antithrombin III (enhancer); Factor Xa and Factor IIa (indirect targets) |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular / Hematology |
| Phase | FDA-approved |
Mechanism of action
Tinzaparin binds to and potentiates antithrombin III, a natural anticoagulant, leading to inactivation of thrombin (factor IIa) and factor Xa. This prevents thrombus formation and propagation. When administered as a continuous infusion, it provides sustained anticoagulation for thromboembolism prevention and treatment.
Approved indications
- Venous thromboembolism (VTE) treatment and prevention
- Deep vein thrombosis (DVT) treatment
- Pulmonary embolism (PE) treatment
Common side effects
- Bleeding
- Thrombocytopenia
- Injection site reactions
- Elevated transaminases
Key clinical trials
- Intravenous Immunoglobulin for the Treatment of Acute Exacerbations of Idiopathic Pulmonary Fibrosis (PHASE3)
- A Study of Amivantamab in Participants With Advanced or Metastatic Solid Tumors Including Epidermal Growth Factor Receptor (EGFR)-Mutated Non-Small Cell Lung Cancer (PHASE2)
- A Dose-Response Controlled Trial of Bevifibatide for Acute Ischemic Stroke (PHASE2)
- Prospective Observational Pilot Study of LMWH Versus UFH as ECMO Anticoagulation in Lung Transplantation
- Comparing Anticoagulation Strategies Using UFH, Argatroban and LMWH for ECMO Support (PHASE4)
- Australasian COVID-19 Trial (ASCOT) ADAptive Platform Trial (PHASE3)
- Viscoelastic Testing Guided Tissue Plasminogen Activator Treatment in Acute Respiratory Failure (PHASE2)
- Efficacy, Safety and Pharmacokinetics of Tinzaparin During Slow Low Efficient Daily Dialysis in Intensive Care Patients (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Tinzaparin continuous infusion CI brief — competitive landscape report
- Tinzaparin continuous infusion updates RSS · CI watch RSS
- Tampere University Hospital portfolio CI